Screener
Ligand Pharmaceuticals LGND EV / EBITDA
EV / EBITDA at other companies
Other financials
Where this comes from
Calculated from Ligand Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
FAQ
- What is Ligand Pharmaceuticals's EV / EBITDA?
- Ligand Pharmaceuticals (LGND) reported EV / EBITDA of 50.6× in Q2 2026.
- How has Ligand Pharmaceuticals's EV / EBITDA changed year-over-year?
- Ligand Pharmaceuticals's EV / EBITDA decreased by 98.5% year-over-year, from 3,429.7× to 50.6×.
- What is the long-term trend for Ligand Pharmaceuticals's EV / EBITDA?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's EV / EBITDA has grown at a 12.9% compound annual growth rate (CAGR), from 25.9× to 47.5×.
- What does EV / EBITDA mean?
- Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.
Ask your AI about Ligand Pharmaceuticals's ev / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude